Protein / target

Osteopontin

Encoded bySPP1P10451Homo sapiensSwiss-Prot

UniProt: P10451 Ensembl: ENSG00000118785 HGNC: HGNC:11255 NCBI Gene: 6696

Clinical-stage

Therapeutic maturity

Clinical candidates

Antibody-tractable

Druggability

Advanced Clinical

Research papers

Protein at a glance

Biological role

Extracellular matrix binding

Strongest disease association

Osteoporosis

Via encoding gene SPP1 · Genetic evidence · score 0.90

Therapeutic position

Clinically advancing target

Antibodies

Research activity

Emerging research

4 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Major non-collagenous bone protein that binds tightly to hydroxyapatite.

View complete UniProt function annotation

Major non-collagenous bone protein that binds tightly to hydroxyapatite. Appears to form an integral part of the mineralized matrix. Probably important to cell-matrix interaction

Subcellular location

Secreted

Domains and Gene Ontology detail (27)

Gene Ontology

Ccell projection
Cendoplasmic reticulum lumen
Cextracellular exosome
Cextracellular region
Cextracellular space
CGolgi apparatus
Cperinuclear region of cytoplasm
Fcalcium ion binding
Fcytokine activity
Fextracellular matrix binding
Fintegrin binding
Fsmall molecule binding

314 aa · 35 kDa · 4 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell adhesionGO

View supporting evidence

Cell adhesion

·extracellular matrix binding
·cell adhesion

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene SPP1

Gene-level evidence surfaced through the gene SPP1that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Osteoporosis

0.92Well supported

Genetic evidence dominant · Open Targets 0.57

Bone Diseases

0.82Well supported

Genetic evidence dominant · Open Targets 0.50

Gout

0.66Moderately supported

Genetic evidence dominant · Open Targets 0.40

Aneurysm

0.60Moderately supported

Genetic evidence dominant · Open Targets 0.36

Aortic Aneurysm

0.59Moderately supported

Genetic evidence dominant · Open Targets 0.36

View evidence synthesis (5)

OsteoporosisWell supported

0.92

agreement 0.80–1.00

Genetic77%Animal model14%Literature8%

Open Targets aggregate 0.57 · 3 independent evidence families

Bone DiseasesWell supported

0.82

agreement 0.68–0.95

Genetic97%Literature3%

Open Targets aggregate 0.50 · 2 independent evidence families

GoutModerately supported

0.66

agreement 0.52–0.80

Genetic92%Literature8%

Open Targets aggregate 0.40 · 2 independent evidence families

AneurysmModerately supported

0.60

agreement 0.46–0.74

Genetic93%Literature7%

Open Targets aggregate 0.36 · 2 independent evidence families

Aortic AneurysmModerately supported

0.59

agreement 0.46–0.73

Genetic96%Literature5%

Open Targets aggregate 0.36 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations

Osteoporosis0.57

Bone Diseases0.50

Gout0.40

Aneurysm0.36

Aortic Aneurysm0.36

Placental abruption0.27

Mouth Diseases0.21

Drug development

1 compounds recorded · 1 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines.

View all recorded compounds (1)

ASK-8007Phase 1 2

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Antibodies — Strong

Advanced Clinical and UniProt loc high conf support this modality.

View underlying tractability evidence (4)

AB · Advanced ClinicalAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMM

Raw Open Targets tractability assessment buckets, by modality.